These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7789255)

  • 1. OV632 as a possible marker for malignant mesothelioma: high expectations; low specificity.
    Abati A; Fetsch PA
    Diagn Cytopathol; 1995 Feb; 12(1):81-2. PubMed ID: 7789255
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor markers for ovarian cancer. A comparative immunohistochemical and immunocytochemical study of two commercial monoclonal antibodies (OV632 and OC125).
    Koelma IA; Nap M; van Steenis GJ; Fleuren GJ
    Am J Clin Pathol; 1988 Oct; 90(4):391-6. PubMed ID: 2459953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of epithelial ovarian neoplasm immunologic reactivity using monoclonal antibodies].
    Bar J; Sobańska E
    Ginekol Pol; 1994 Sep; 65(9):502-7. PubMed ID: 7721163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
    Delahaye M; Hoogsteden HC; Van der Kwast TH
    J Pathol; 1991 Oct; 165(2):137-43. PubMed ID: 1744800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunodiagnosis of ovarian tumors.
    Jacobs I; Bast RC
    Immunol Ser; 1990; 53():323-38. PubMed ID: 2100566
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunocytochemical detection of ovarian carcinoma cells in serous effusions.
    Cuijpers VM; Boerman OC; Salet van de Pol MR; Vooijs GP; Poels LG; Ramaekers FC
    Acta Cytol; 1993; 37(3):272-9. PubMed ID: 8498129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The usefulness of CYFRA 21-1 in diagnosing and monitoring malignant pleural mesothelioma.
    Marukawa M; Hiyama J; Shiota Y; Ono T; Sasaki N; Taniyama K; Mashiba H
    Acta Med Okayama; 1998 Apr; 52(2):119-23. PubMed ID: 9588228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunocytochemical staining of ovarian tumours with Ov632.
    Owens OJ; Mutch F
    Cytopathology; 1992; 3(3):161-6. PubMed ID: 1511121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
    Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
    Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of epithelial ovarian-cancer-associated antigens involved in immune complexes by monoclonal antibodies.
    Kawata M; Sekiya S
    Tumour Biol; 1998; 19(1):1-11. PubMed ID: 9422077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of anticarcinoembryonic antigen, human milk factor globulin, and antikeratin antibodies in differentiating mesothelioma from lung carcinoma.
    Joglekar VM; Oliver D; Harris M
    Br J Ind Med; 1991 Jan; 48(1):34-7. PubMed ID: 1704251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies against mesothelial membrane antigen discriminate between malignant mesothelioma and lung adenocarcinoma.
    Stahel RA; O'Hara CJ; Waibel R; Martin A
    Int J Cancer; 1988 Feb; 41(2):218-23. PubMed ID: 3276635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunophenotyping of malignant mesothelioma.
    Wick MR
    Am J Surg Pathol; 1997 Dec; 21(12):1395-8. PubMed ID: 9414182
    [No Abstract]   [Full Text] [Related]  

  • 14. Calretinin and other mesothelioma markers in synovial sarcoma: analysis of antigenic similarities and differences with malignant mesothelioma.
    Miettinen M; Limon J; Niezabitowski A; Lasota J
    Am J Surg Pathol; 2001 May; 25(5):610-7. PubMed ID: 11342772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma.
    Paganuzzi M; Onetto M; Marroni P; Filiberti R; Tassara E; Parodi S; Felletti R
    Chest; 2001 Apr; 119(4):1138-42. PubMed ID: 11296181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of ovarian tumor antigen NB/70K: monoclonal antibody assays for distinguishing ovarian cancer from other gynecologic disease.
    Knauf S
    Am J Obstet Gynecol; 1988 May; 158(5):1067-72. PubMed ID: 3369485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Newly marketed tissue markers for malignant mesothelioma: immunoreactivity of rabbit AMAD-2 antiserum compared with monoclonal antibody HBME-1 and a review of the literature on so-called antimesothelioma antibodies.
    Donna A; Betta PG; Chiodera P; Bellingeri D; Libener R; Zorzi F; Tassi GF
    Hum Pathol; 1997 Aug; 28(8):929-37. PubMed ID: 9269829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of ovarian carcinoma OV632 antigen by interferons.
    Marth C; Müller-Holzner E; Gaugg I; Daxenbichler G; Dapunt O
    Oncology; 1992; 49(1):53-7. PubMed ID: 1542495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma.
    Bast RC; Knapp RC
    Important Adv Oncol; 1987; ():39-53. PubMed ID: 3331386
    [No Abstract]   [Full Text] [Related]  

  • 20. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
    Ho M; Hassan R; Zhang J; Wang QC; Onda M; Bera T; Pastan I
    Clin Cancer Res; 2005 May; 11(10):3814-20. PubMed ID: 15897581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.